Skip to main content

MDI, Launch Diagnostics Distributing MRSA Test

a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Molecular Detection and Launch Diagnostics today announced an exclusive distribution agreement for MDI's real-time PCR-based diagnostic for methicillin-resistant Staphylococcus aureus.

The agreement covers the UK, France, and Republic of Ireland. Other terms of the agreement were not disclosed.

The two firms also announced that the test, called Detect-Ready MRSA, has been launched in the UK and the Republic of Ireland.

Detect-Ready MRSA is a qualitative RT-PCR in vitro diagnostic test for detecting MRSA nasal colonization and is used to help prevent bacterial infection in hospitals and other healthcare settings.

Based in Wayne, Pa., MDI develops molecular diagnostic tests. Launch Diagnostics, headquartered in Longfield, UK, is a distributor of reagents, instruments, and related consumables.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.